Apheresis in coronary heart disease with elevated Lp (a): A review of Lp (a) as a risk factor and its management

Therapeutic Apheresis and Dialysis

Volumn 11, Issue 1, 2007, Pages 2-8

  Keller, Christiane ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Coronary heart disease; Epidemiology of Lp (a); LDL apheresis; Lp (a) apheresis

Indexed keywords

ACETYLCYSTEINE; ACID CITRATE DEXTROSE; ASCORBIC ACID; BEZAFIBRATE; DEXTRAN SULFATE; HEPARIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; NEOMYCIN; NICOTINIC ACID; PRAVASTATIN;

APHERESIS; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL STUDY; CORONARY ARTERY DISEASE; DISEASE COURSE; DOSE RESPONSE; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MEDICAL LITERATURE; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; REVIEW; RISK MANAGEMENT; TECHNICAL AID; VASCULAR DISEASE;

ANIMALS; BLOOD COMPONENT REMOVAL; CHOLESTEROL, LDL; CORONARY ANGIOGRAPHY; CORONARY DISEASE; HUMANS; LIPOPROTEIN(A); PLASMA VOLUME; RISK FACTORS;

EID: 33847005410     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2007.00449.x     Document Type: Review

References (45)

1. Berg K. A new serum type system in man: the Lp system. Acta Pathol Microbiol Scand 1963;59:369-82.
2. Marcovina SM, Koschinsky ML, Albers JJ et al. Report of the National Heart, Lung, and Blood Institute workshop on lipoprotein (a) and cardiovascular disease: recent advances and future directions. Clin Chem 2003;49:1785-96.
3. McLean JW, Tomlinson JE, Kuang W-J et al. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature 1987;330:132-7.
4. Scanu AM, Fless GM. Lipoprotein (a). Heterogeneity and biological relevance. J Clin Invest 1990;85:1709-15.
5. Utermann G, Menzel HJ, Kraft HG et al. Lp (a) glycoprotein phenotypes. Inheritance and relation to Lp (a) -lipoprotein concentration in plasma. J Clin Invest 1987;80:458-65.
6. Nguyen TT, Ellefson RD, Hodge DO et al. Predictive value of electrophoretically detected lipoprotein (a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation 1997;96:1390-7.
7. Craig WY, Neveux LM, Palomaki GE et al. Lipoprotein (a) as a risk factor for ischemic heart disease: meta-analysis of prospective studies. Clin Chem 1998;44:2301-6.
8. Danesh J, Collins R, Peto R. Lipoprotein (a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000;102:1082-5.
9. Obisean TO, Aliyu MH, Adediran AS et al. Correlates of serum lipoprotein (a) in children and adolescents in the United States. The third National Health Nutrition and Examination Survey (NHANES-III). Lipids Health Dis 2004;3:29-39.
10. Sandkamp M, Funke H, Schulte H et al. Lipoprotein (a) is an independent risk factor for myocardial infarction at a young age. Clin Chem 1990;36:20-3.
11. Lawn RM, Pearle AD, Kunz LL et al. Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein (a) mice. J Biol Chem 1996;271:31367-71.
12. Sun H, Unoki H, Wang X et al. Lipoprotein (a) enhances advanced atherosclerosis and vascular calcification in WHHL transgenic rabbits expressing human apolipoprotein (a). J Biol Chem 2002;277:47486-92.
13. Lundstam U, Hurt-Camejo E, Olsson G et al. Proteoglycans contribution to association of Lp (a) and LDL with smooth muscle cell extracellular matrix. Arterioscler Thromb Vasc Biol 1999;19:1162-7.
14. Allen S, Khan Sh, Shui-Pang T et al. Expression of adhesion molecules by Lp (a): a potential novel mechanism for its atherogenicity. FASEB J 1998;12:1765-76.
15. Tsurumi Y, Nagashima H, Ichikawa K-I et al. Influence of plasma lipoprotein (a) levels on vasomotor response to acetylcholine. J Am Coll Cardiol 1995;26:1242-50.
16. Dangas G, Mehran R, Harpel P et al. Lipoprotein (a) and inflammation in human coronary atheroma: association with the severity of clincal presentation. J Am Coll Cardiol 1998;32:2035-42.
17. Desmarais RL, Sarembock IJ, Ayers CR et al. Elevated serum lipoprotein (a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation 1995;91:1403-9.
18. Pokrovsky SN, Ezhov MV, Afanasieva OI et al. Association of lipoprotein (a) excess with early vein graft occlusions in middle-aged men undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003;126:1071-5.
19. Budde T, Fechtrup C, Bosenberg C et al. Plasma Lp (a) levels correlate with number, severity, and length-extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1994;14:1730-6.
20. Babir M, Kushwaha S, Hunt B et al. Lipoprotein (a) and accelerated coronary artery disease in cardiac transplant recipients. Lancet 1992;340:1500-2.
21. Otto C, Kern P, Bambauer R et al. Efficacy and safety of a new whole-blood low-density lipoprotein apheresis system (Liposorber D) in severe hypercholesterolemia. Artif Organs 2003;27:1116-22.
22. Hiroyuki D, Young JL, Hisashi Y et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein (a) levels with low-density lipoprotein apheresis. Am J Cardiol 1994;73:1037-40.
23. Ullrich H, Lackner K, Schmitz G. Lipoprotein (a) - apheresis in the secondary prevention of coronary heart disease. Transfus Sci 1996;17:511-17.
24. Pokrovsky SN, Adamova IY, Afanasieva OI et al. Immunosorbent for selective removal of lipoprotein (a) from human plasma: in vitro study. Artif Organs 1991;15:136-46.
25. Pokrovsky SN, Sussekov AV, Afanasieva OI et al. Extracorporeal immunoadsorption for the specific removal of lipoprotein (a) (Lp (a) apheresis): preliminary clinical data. Chem Phys Lipids 1994;67:323-30.
26. Kojima S. Low-density lipoprotein apheresis and changes in plasma components. Ther Apher 2001;5:232-8.
27. Parhofer KG, Demant T, Ritter MM, Geiss HC, Donner M, Schwandt P. Lipoprotein (a) metabolism estimated by non-steady-state kinetics. Lipids 1999;34:325-35.
28. Bosch T, Lennertz A, Schenzle D et al. Direct adsorption of low-density lipoprotein and lipoprotein (a) from whole blood: results of the first clinical long-term multicenter study using DALI apheresis. J Clin Apher 2002;17:161-9.
29. Armstrong VW, Schuff-Werner P, Eisenhauer T et al. Heparin extracorporeal LDL precipitation (HELP): an effective apheresis procedure for lowering Lp (a) levels. Chem Phys Lipids 1994;67:315-21.
30. Richter WO, Donner M, Schwandt P. Three low density lipoprotein apheresis techniques in treatment of patients with familial hypercholesterolemia: a long-term evaluation. Ther Apher 1999;3:203-8.
31. Parhofer KG, Geiss HC, Schwandt P. Efficacy of different low-density lipoprotein apheresis methods. Ther Apher 2000;4:382-5.
32. Thompson GR. LDL apheresis. Atherosclerosis 2003;167:1-13.
33. Ritter MM, Sühler K, Richter WO, Schwandt P. Short- and long-term effects of LDL-apheresis on lipoprotein (a) serum levels. Clin Chim Acta 1990;195:9-15.
34. Kroon AA, van't Hof MA, Demacker PNM et al. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Atherosclerosis 2000;152:519-26.
35. Sachais BS, Katz J, Ross J, Rader DJ. Long-term effects of LDL apheresis in patients with severe hypercholesterolemia. J Clin Apher 2005;20:252-5. DOI. 10.1002/jca.20036.
36. Bosch T, Keller C. Clinical effects of direct adsorption of lipoprotein apheresis: beyond cholesterol reduction. Ther Apher Dial 2003;7:341-4.
37. Blessing F, Ying W, Walli AK et al. Heparin-mediated extracorporeal low-density lipoprotein precipitation: rationale for a specific adjuvant therapy in cardiovascular disease. Transfus Apher Sci 2004;30:255-66.
38. Berglund L, Ramakrishnan R. Lipoprotein (a). An elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol 2004;24:2219-26.
39. Luc G, Bard J-M, Arveiler D et al. Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis 2002;163:377-84.
40. Seman LJ, DeLuca C, Jenner JL et al. Lipoprotein (a)-cholesterol and coronary heart disease in the Framingham Heart Study. Clin Chem 1999;45:1039-46.
41. Hopkins PN, Wu LL, Hunt SC et al. Lipoprotein (a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. Arterioscl Thromb Vasc Biol 1997;17:2783-92.
42. Kronenberg F, Kronenberg MF, Kiechl S et al. Role of lipoprotein (a) and apolipoprotein (a) phenotype in atherogenesis. Prospective results from the Bruneck study. Circulation 1999;100:1154-60.
43. Bambauer R. Low-density lipoprotein apheresis: clinical results with different methods. Artif Organs 2002;26:133-9.
44. Donner MG, Richter WO, Schwandt P. Plama lipoproteins under LDL apheresis by cascade filtration. Abstract 209, 66th EAS Meeting, Florence 1996.
45. Gordon BR, Kelsey SF, Dau PC et al. Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automatic dextran sulfate cellulose adsorption system. Am J Cardiol 1992;70:1010-16.